文献速递心境障碍

特异性心理治疗对比非特异性心理治疗对慢性抑郁症的疗效:一项随机临床试验

Effect of Disorder-Specific vs Nonspecific Psychotherapy for Chronic Depression: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2017-01-01

该多中心、评估者盲法随机临床试验纳入268例未服用抗抑郁药的早发性慢性抑郁症门诊患者,比较认知行为分析系统心理治疗(CBASP)与支持性心理治疗(SP)的疗效。结果显示,20周时CBASP组HRSD-24评分改善显著优于SP组(调整后均差-2.51,95%CI -4.16至-0.86;

要点

  • 对于未服药的早发性慢性抑郁症门诊患者,CBASP在改善抑郁症状方面优于支持性心理治疗。
  • CBASP组20周应答率和缓解率显著高于SP组,且疗效在48周时仍维持。
  • 在急性期治疗后增加巩固期治疗可能对该人群有益。

核心结论

  • 高度结构化的特异性心理治疗(CBASP)对未服用抗抑郁药的早发性慢性抑郁症门诊患者的疗效中等程度优于非特异性心理治疗(SP)。

研究设计与样本

  • 前瞻性、多中心、评估者盲法随机临床试验,纳入268例未服用抗抑郁药的早发性慢性抑郁症成人门诊患者,随机分配至CBASP组(137例)或SP组(131例)。

关键数值与推荐

  • 主要结局为20周时盲法评估的24项汉密尔顿抑郁量表(HRSD-24)症状严重程度。
  • 应答定义为HRSD-24评分较基线下降≥50%,缓解定义为HRSD-24评分≤8。
  • 治疗包括20周急性期24次治疗,随后28周8次巩固治疗。

临床怎么用

  • 对于未服药的早发性慢性抑郁症门诊患者,可考虑选用CBASP这种高度结构化的特异性心理治疗。
  • 在急性期心理治疗后增加巩固期治疗可能有助于维持疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Chronic depression is a highly prevalent and disabling disorder. There is a recognized need to assess the value of long-term disorder-specific psychotherapy. OBJECTIVE: To evaluate the efficacy of the Cognitive Behavioral Analysis System of Psychotherapy (CBASP) compared with that of nonspecific supportive psychotherapy (SP). DESIGN, SETTING, AND PARTICIPANTS: A prospective, multicenter, evaluator-blinded, randomized clinical trial was conducted among adult outpatients with early-onset chronic depression who were not taking antidepressant medication. Patients were recruited between March 5, 2010, and October 16, 2012; the last patient finished treatment on October 14, 2013. Data analysis was conducted from March 5, 2014, to October 27, 2016. INTERVENTIONS: The treatment included 24 sessions of CBASP or SP for 20 weeks in the acute phase, followed by 8 continuation sessions during the next 28 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was symptom severity after 20 weeks (blinded observer ratings) as assessed by the 24-item Hamilton Rating Scale for Depression (HRSD-24). Secondary outcomes were rates of response (reduction in HRSD-24 score of ≥50% from baseline) and remission (HRSD-24 score ≤8), as well as self-assessed ratings of depression, global functioning, and quality of life. RESULTS: Among 622 patients assessed for eligibility, 268 were randomized: 137 to CBASP (96 women [70.1%] and 41 men [29.9%]; mean [SD] age, 44.7 [12.1] years) and 131 to SP (81 women [61.8%] and 50 men [38.2%]; mean [SD] age, 45.2 [11.6] years). The mean (SD) baseline HRSD-24 scores of 27.15 (5.49) in the CBASP group and 27.05 (5.74) in the SP group improved to 17.19 (10.01) and 20.39 (9.65), respectively, after 20 weeks, with a significant adjusted mean difference of -2.51 (95% CI, -4.16 to -0.86; P = .003) and a Cohen d of 0.31 in favor of CBASP. After 48 weeks, the HRSD-24 mean (SD) scores were 14.00 (9.72) for CBASP and 16.49 (9.96) for SP, with an adjusted difference of -3.13 (95% CI, -5.01 to -1.25; P = .001) and a Cohen d of 0.39. Patients undergoing CBASP were more likely to reach response (48 of 124 [38.7%] vs 27 of 111 [24.3%]; adjusted odds ratio, 2.02; 95% CI, 1.09 to 3.73; P = .03) or remission (27 of 124 [21.8%] vs 14 of 111 [12.6%]; adjusted odds ratio, 3.55; 95% CI, 1.61 to 7.85; P = .002) after 20 weeks. Patients undergoing CBASP showed significant advantages in most other secondary outcomes. CONCLUSIONS AND RELEVANCE: Highly structured specific psychotherapy was moderately more effective than nonspecific therapy in outpatients with early-onset chronic depression who were not taking antidepressant medication. Adding an extended phase to acute psychotherapy seems promising in this population. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00970437.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Schramm E, Kriston L, Zobel I, et al. Effect of Disorder-Specific vs Nonspecific Psychotherapy for Chronic Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2017. PMID: 28146251. doi:10.1001/jamapsychiatry.2016.3880

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。